Page last updated: 2024-11-12

talisomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

talisomycin: contains components A & B; glycopeptide related to bleomycin antibiotic from actinomycetes strain 6465-94; RN given refers to cpd with unknown MF [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID134129844
CHEMBL ID3989770
MeSH IDM0065898

Synonyms (3)

Synonym
talisomycin
nsc-279496
CHEMBL3989770

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The relative therapeutic and toxic effects of two new analogs were compared with bleomycin over a range of doses."( Relative pulmonary toxicity and antitumor effects of two new bleomycin analogs, pepleomycin and tallysomycin A.
Gram, TE; Siddik, ZH; Sikic, BI,
)
0.13
"Tallysomycin S10b (TLM S10b), a structural analog of bleomycin (BLM), was evaluated and compared with BLM for antitumor activity in several murine tumor systems and for toxic effects in mice and rats."( Tallysomycin S10b: experimental antitumor activity and toxicity.
Bradner, WT; Florczyk, AP; Hirth, RS; Huftalen, JB; Rose, WC; Schlein, A; Schurig, JE, 1984
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" The slower elimination of talisomycin was reflected by a half-life (t1/2) of 10."( Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey.
Hottendorf, GH; Lee, FH; Smyth, RD; Strong, JE; Van Harken, DR, 1981
)
0.26

Dosage Studied

ExcerptRelevanceReference
" The sensitivities of asynchronous and synchronous cells to TLM and BLM were expressed as biphasic dose-response survival curves."( Comparison of the response of synchronized HeLa cells to talisomycin and bleomycin.
Crooke, ST; Mirabelli, CK, 1981
)
0.26
" Both drugs caused dose-related increases in the whole-lung hydroxyproline content in mice, but the dose-response curves were not parallel."( Tallysomycin S10b: experimental antitumor activity and toxicity.
Bradner, WT; Florczyk, AP; Hirth, RS; Huftalen, JB; Rose, WC; Schlein, A; Schurig, JE, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (72.92)18.7374
1990's6 (12.50)18.2507
2000's4 (8.33)29.6817
2010's3 (6.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (96.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]